Rosetta Inpharmatics, Inc. Company Profile | Company Information

proklofuxaanygez.blogspot.com
Rosetta Inpharmatics LLC, a wholly owned subsidiar of Merck & Co. Inc., develops and implementd technologies that will improve drug The company's leading-edge genomic researchb and data analysis efforts focus on how medicalo compounds affect biology, enabling more accurate selectionm of drug targets and more efficient drug development. Rosetta Inpharmatics was foundedd in 1996 to design and implement DNA microarray geneexpressionj technologies. The company was established with the goal to overcomed the problems limiting the discovery and effectiv development of pharmaceutical andagriculturap products. The founders include: Stephen H. M.D., Ph.D., the company's president; Leland Hartwell, Ph.
D., and Lerogy Hood, M.D., Ph.D. Rosetta Inpharmatics' technologh and patent portfolio were enhanced by its purchase ofAcaciaa Biosciences, Inc. in February 1999, a company foundedf by Jasper Rine, Ph.D. In October the Company signed a strategic partnership agreement with Agilent Technologies to furthed develop and commercializeRosetta Inpharmatics' DNA As part of this agreement, Agilent made a significant equitgy investment in Rosetta Inpharmatics. In June Rosetta Inpharmatics successfully deployed its firsyt commercially availablebioinformatics system, the Rosetta ResolverA Gene Expressionh Data Analysis System.
The Rosetta Resolvert system was introduced to meet the demandfor high-level gene expression analysis within the life